Article

Hyaluronidase injection approved by FDA

Rancho Cucamonga, CA-The drought may be over for ophthalmic surgeons who used Wydase, a hyaluronidase injection discontinued by its manufacturer in 2001, to speed the onset of anesthesia.

Rancho Cucamonga, CA-The drought may be over for ophthalmic surgeons who used Wydase, a hyaluronidase injection discontinued by its manufacturer in 2001, to speed the onset of anesthesia.

The FDA has approved a new hyaluronidase injection USP in 150 units/ml, in 1-ml vials, by Amphastar Pharmaceuticals Inc. that the company said has properties and side effects similar to Wydase. Amphastar has begun to ship Amphadase directly and through major drug wholesalers.

Hyaluronidase is an enzyme that breaks down hyaluronic acid in connective tissue, increasing tissue permeability. It is often used to facilitate the dispersion and absorption of other drugs, especially in nerve-block anesthesia and anesthesia before ophthalmic surgery.

Also, ISTA Pharmaceuticals Inc., Irvine, CA, announced Dec. 3 that the FDA has approved a single-use vial size of 200 USP units/ml of its hyaluronidase injection (Vitrase) ovine sterile solution for use as a spreading agent to facilitate the dispersion and absorption of other drugs. ISTA's product is a proprietary formulation of highly purified, preservative-free ovine hyaluronidase, which has been studied extensively in several ophthalmic conditions.

The company anticipates it will launch the new vial size, as well as the previously approved 6,200 USP units multi-purpose vial, early in the first quarter of 2005, said Vicente Anido Jr., PhD, ISTA's chief executive officer, in a prepared statement.

According to an American Academy of Ophthalmology roundtable discussion posted online, Wydase was used in about 750,000 procedures in 1999, and its withdrawal from the market sent "shock waves" throughout the ophthalmic community. Surgeons said they used it most often to reduce the amount of anesthesia required for cataract surgery.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
© 2025 MJH Life Sciences

All rights reserved.